EDVA · Endovia Health Sciences, Inc.
$0.25
+0.01 (+2.13%)
At close · Sep 11
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for the next 12 months.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.60M
Shares
6.41M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.25
Open$0.25
Day$0.24–0.26
52W close$0.24–10.16
Avg vol 30d3.7M
Short int228K · 3.6% float · 1.0d
Short vol67%
Last earningsSep 30, 2024
DataJan 2020–Sep 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$32,090
Trailing 12 months
Net income (TTM)
−$17.28M
Trailing 12 months
Revenue growth YoY
-93.8%
Year over year
Operating margin
-19,415.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+545.3%
Year over year · more shares
Price change (1Y)
-96.5%
Trailing year
Short interest
3.6%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−86%
below
Price vs 50-day avg
−42%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−88%
trailing
YTD return
−91%
this year
Relative strength
−106%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.56% of float · ▼ -50.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
35
low risk · 0–100
Fundamentals
Revenue growth
−91%
Y/Y
Gross margin
23%
expanding
EPS growth
+32%
Y/Y
Balance sheet
$37.4K
net cash
Quant / Vol
risk profile
Volatility
189%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
21.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−86%
Bearish
Price vs 50-day avg
−42%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.56% of float · ▼ -50.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $10
vs 200-day avg -86%
vs 50-day avg -42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDVA
this stock
Endovia Health Sciences, Inc.
|
$1.60M | -91.0% | -90.9% | — | 3.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDVA | -7.4% | -36.8% | -88.0% | -17.5% | -91.0% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -6.2% | -35.0% | -105.9% | -17.1% | -103.1% |